- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05660785
Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia
The Efficacy and Safety of Herombopag Combined With Cyclosporine for Patients With Non Severe Aplastic Anemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lele Zhang, PhD
- Phone Number: 15811139278
- Email: zhanglele@ihcams.ac.cn
Study Locations
-
-
Hebei
-
Tangshan, Hebei, China
- Not yet recruiting
- Tangshan Central Hospital
-
Contact:
- Jun Li
- Phone Number: 15030531816
- Email: 769164130@qq.com
-
-
Henan
-
Zhoukou, Henan, China
- Not yet recruiting
- Zhoukou Central Hospital
-
Contact:
- Qian Liang, PhD
- Phone Number: 15703815972
- Email: lqw141230@163.com
-
-
Shandong
-
Tai'an, Shandong, China
- Not yet recruiting
- The Second Affilated Hospital of Shandong First Medical University
-
Contact:
- Hong Zhang
- Phone Number: 18505386878
- Email: tyfyzhh@163.com
-
-
Tianjin
-
Tianjin, Tianjin, China
- Recruiting
- Regenerative Medicine Center
-
Contact:
- Lele Zhang, PhD
- Phone Number: 15811139278
- Email: zhanglele@ihcams.ac.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to comply with the requirements for this study and written informed consent.
- Male or female age ≥ 18 years
- Diagnosis of untreated non severe aplastic anemia.
- Platelet counts < 50 x 10^9/L at least 2 times consecutively (time interval ≥ 1 week)
Exclusion Criteria:
- Receive immunosuppressive therapy more than 4 weeks before enrollment
- Treatment with TPO-RA within 1 week before enrollment
- Inherited bone marrow failure syndromes
- Bone marrow fibrosis grade ≥ 2
- The presence of hemolytic PNH clone
- The presence of clonal karyotypic abnormalities (del(20q), +8 and -Y are not included in this category)
- Previously treated with TPO-RA ≥ 4 weeks
- Previously received immunosuppressive therapy ≥ 12 weeks
- Ferritin > 1000 ng/ml (The increased level of Ferritin led by infection is not included in this category)
- Have an allergy to eltrombopag or any other part of this medicine.
- History of radiotherapy and chemotherapy for malignant solid tumors
- Cytopenia caused by other non-hematologic diseases, including liver cirrhosis, active rheumatic connective tissue disease, and persistence of infectious diseases, etc
- Abnormal liver function: ALT or AST > 3 ULN, or TBil > 1.5 ULN after treatment.
- Abnormal kidney function: Creatinine clearance < 30 ml/min, or serum creatinine (sCr) >1.5 ULN
- Patients with diabetic nephropathy, neuropathy, or eye disease
- Patients with poorly controlled hypertension or cardiac arrhythmia
- Patients with congestive heart failure and the NYHA grade ≥ 3 historically or currently, and LVEF < 45% within 4 weeks before enrollment
- History of arteriovenous thrombosis within 1 year before enrollment
- Participation in another clinical trial within 4 months before the start of this trial
- Pregnant or breast-feeding patients
- Patients considered to be ineligible for the study by the investigator for reasons other than the above
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CsA + Herombopag
Herombopag combined with cyclosporine
|
Hetrombopag is a TPO receptor agonist approved in China in 2021 for idiopathic thrombocytopenic purpura (ITP) and second-line severe aplastic anemia (SAA). Indications of chemotherapy-induced thrombocytopenia (CIT), pediatric/juvenile ITP and naive severe aplastic anemia are under development. Hetrombopag was granted Orphan Drug Designation by FDA for the treatment of CIT. Cyclosporine A is a calcineurin inhibitor, which has an effect on reducing T-cell proliferation and activation, can reverse pancytopenia and alleviate transfusion requirements in NSAA.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall response rate
Time Frame: 24 weeks
|
Percentage of patients with hematological response.
Hematological response is evaluated by hemoglobin, platelet and neutrophil count in the routine blood test.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Robust response rate
Time Frame: 24 weeks
|
Percentage of patients with robust response, including complete response, near complete response, very good partial response(VGPR) and Meaningful partial response(mPR).
These are evaluated by hemoglobin, platelet and neutrophil count in the routine blood test.
|
24 weeks
|
Proportion of patients with abnormal karyotype changes
Time Frame: Baseline and 24 weeks
|
The abnormal karyotype was examined by karyotype test
|
Baseline and 24 weeks
|
Time duration for patients achieving hematological response
Time Frame: A minimum of 2 years of planned follow-up
|
Duration time was calculated from response to relapse.
|
A minimum of 2 years of planned follow-up
|
Change of the health-related quality of life
Time Frame: Baseline and 24 weeks
|
Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) is used to assess the health-related quality of life of patients.
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section.
Scores range from 0 - 100.
Lower scores = more disability, higher scores = less disability
|
Baseline and 24 weeks
|
Incidence of the adverse event
Time Frame: 24 weeks
|
Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event.
|
24 weeks
|
Severity of the adverse event
Time Frame: 24 weeks
|
Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the severity.
|
24 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Marrow Diseases
- Hematologic Diseases
- Bone Marrow Failure Disorders
- Anemia
- Anemia, Aplastic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antirheumatic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- MA-NSAA-II-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Severe Aplastic Anemia
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Peking Union Medical College HospitalNot yet recruitingNon Severe Aplastic AnemiaChina
-
University of UtahNovartisCompletedSevere Aplastic Anemia | Moderate Aplastic Anemia | Very Severe Aplastic AnemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Severe Aplastic Anemia | Refractory Severe Aplastic AnemiaUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedSevere Aplastic Anemia, Refractory | Severe Aplastic Anemia, RelapseUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Peking University People's HospitalRecruiting
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingSevere Aplastic AnemiaUnited States
-
Shanghai General Hospital, Shanghai Jiao Tong University...Ruijin Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine and other collaboratorsCompleted
-
Navy General Hospital, BeijingPeking Union Medical College Hospital; Cancer Institute and Hospital, Chinese... and other collaboratorsUnknownSevere Aplastic AnemiaChina
Clinical Trials on Herombopag
-
Peking Union Medical College HospitalNot yet recruiting
-
Second Hospital of Shanxi Medical UniversityNot yet recruitingTumor Chemotherapy-related ThrombocytopeniaChina
-
The First Affiliated Hospital of Zhengzhou UniversityJiangsu HengRui Medicine Co., Ltd.Not yet recruitingTumor Therapy-related Thrombocytopenia
-
Yin JieRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdult Patients With Chronic Primary ITP | Adult Patients With SAA Who do Not Respond Well to Immunosuppressive Therapy
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingImmune Thrombocytopenia
-
SuxiaLuoRecruiting
-
Henan Cancer HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Hebei Medical University Fourth HospitalNot yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingAdult Patients With Chronic Primary ITP | Adult Patients With SAA Who do Not Respond Well to Immunosuppressive TherapyChina